Dynavax Technologies Corporation, a biopharmaceutical company
focused on developing and commercializing novel vaccines, and Times
Pharmacy, have partnered with Hep Free Hawaii to provide HEPLISAV-B
[Hepatitis B Vaccine (Recombinant), Adjuvanted] at pharmacy
locations on Oahu, with a focus on people living with diabetes.
Through this partnership, pharmacy customers will have access to
HEPLISAV-B, the only FDA-approved two-dose hepatitis B vaccine for
adults that is completed in one month. HEPLISAV-B is indicated for
prevention of infection caused by all known subtypes of hepatitis B
virus in adults age 18 years and older.
“Our goal is to eliminate hepatitis B in Hawaii, which includes
vaccinating at-risk populations, such as people with diabetes,”
said Thaddeus Pham, co-Founder and co-Director of the Hep Free
Hawaii Coalition. “Preventing hepatitis B through immunization is
an important part of preventive care and is critical to slowing the
spread of hepatitis B, which will also help protect against new
cases of liver cancer.”
It is estimated that half of the adults in Hawaii have type 2
diabetes or prediabetesi, which lowers the efficiency of the immune
system and can make people more susceptible to viral infections,
such as hepatitis B. Hepatitis B is also one of the leading causes
of liver cancer and Hawaii has the second highest number of cases
of liver cancer and deaths in the U.S.ii”
“At Times Pharmacy, our customers are relying on us more than
ever, and this partnership further demonstrates our commitment to
providing them the best care possible,“ said Melissa Machida,
Clinical Pharmacy Manager at Times Pharmacy. “One way to help
protect our customers from the long-term consequences of this
vaccine-preventable disease, such as cirrhosis and liver cancer, is
to provide immunization from hepatitis B. HEPLISAV-B is a two-dose
vaccination series spaced apart by only one month, providing higher
protection rates than previous hepatitis B vaccination
options.”
Hepatitis B is a liver infection caused by the hepatitis B virus
(HBV). In the U.S., it is estimated that 15 to 25 percent of
patients with chronic hepatitis B develop chronic liver disease,
including cirrhosis, liver failure, or liver cancer.iii People
living with diabetes are at increased risk for hepatitis B since
the hepatitis B virus can be spread through everyday disease
management activities such as sharing blood glucose meters,
fingerstick devices or other diabetes-care equipment including
syringes or insulin pens.iv The CDC recommends HBV vaccination for
all adults with diabetes who are younger than 60 years old.v
“Community pharmacists see their patients regularly and, as
such, they play such a critical role when it comes to vaccinating
patients in their neighborhood,” said Donn Casale, Vice
President, Commercial of Dynavax. “We are pleased Times Pharmacy
recognized that HEPLISAV-B can provide the fastest and highest
rates of protection for their customers at risk.”
Vaccination with HEPLISAV-B will be available at four Times
Pharmacy locations including Times Koolau, Times Waimalu, Times
Kunia, and Times Kamehameha Shopping Center locations during normal
business hours and no appointments are necessary. Private insurers,
Medicare and Medicaid are required to cover preventative HBV
testing and vaccines, usually without a deductible or co-pay. Payer
coverage for HEPLISAV-B has been established for 100% of Medicare
lives, more than 95% of Commercial lives, and 90% of Medicaid
fee-for-service lives. Times Pharmacy is practicing COVID 19 safety
measures.
Please see Important Safety Information below.
For more information about HEPLISAV-B,
visit http://heplisavb.com/.
About Hepatitis B Hepatitis B is a viral
disease of the liver that can become chronic and lead to cirrhosis,
liver cancer and death. The hepatitis B virus is 50 to 100 times
more infectious than HIV,vi and transmission is on the rise. There
is no cure for hepatitis B, but effective vaccination can prevent
the disease.
In adults, hepatitis B is spread through contact with infected
blood and through unprotected sex with an infected person. The CDC
recommends vaccination for those at high risk for infection due to
their jobs, lifestyle, living situations and travel to certain
areas.vii Because people with diabetes are particularly vulnerable
to infection, the CDC recommends vaccination for adults age 19 to
59 with diabetes as soon as possible after their diagnosis, and for
people age 60 and older with diabetes at their physician's
discretion.viii Approximately 20 million U.S. adults have diabetes,
and 1.5 million new cases of diabetes are diagnosed each
year.ix
About HEPLISAV-B HEPLISAV-B is an adult
hepatitis B vaccine that combines hepatitis B surface antigen
with Dynavax's proprietary Toll-like Receptor (TLR) 9
agonist to enhance the immune response. Dynavax has
worldwide commercial rights to HEPLISAV-B.
Indication and Use HEPLISAV-B is
indicated for prevention of infection caused by all known subtypes
of hepatitis B virus in adults age 18 years and older.
Important Safety Information (ISI) Do not
administer HEPLISAV-B to individuals with a history of severe
allergic reaction (e.g., anaphylaxis) after a previous dose of any
hepatitis B vaccine or to any component of HEPLISAV-B, including
yeast.
Appropriate medical treatment and supervision must be available
to manage possible anaphylactic reactions following administration
of HEPLISAV-B.
Immunocompromised persons, including individuals receiving
immunosuppressant therapy, may have a diminished immune response to
HEPLISAV-B.
Hepatitis B has a long incubation period. HEPLISAV-B may not
prevent hepatitis B infection in individuals who have an
unrecognized hepatitis B infection at the time of vaccine
administration.The most common patient reported adverse reactions
reported within 7 days of vaccination were injection site pain (23%
to 39%), fatigue (11% to 17%) and headache (8% to 17%).
For full Prescribing Information for
HEPLISAV-B, click here.
About Dynavax Dynavax is a commercial
stage biopharmaceutical company developing and commercializing
novel vaccines. The Company launched its first commercial product,
HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], in
February 2018, following U.S. FDA approval for prevention of
infection caused by all known subtypes of hepatitis B virus in
adults age 18 years and older. Dynavax is also further
developing CpG 1018 as an advanced vaccine adjuvant through
research collaborations and partnerships. Current collaborations
are focused on adjuvanted vaccines for COVID-19 and pertussis. For
more information, visit www.dynavax.com and follow the
company on LinkedIn.
Media Contact Elizabeth FatonePh. (310)
963-5221ElizabethFatone@SamBrown.com
Investor ContactNicole ArndtPh. (510)
665-7264narndt@dynavax.com
____________________________
i Hawaii State Department of Health.
https://www.healthyhawaii.com/prevent-diabetes-2/ii CDC.
https://gis.cdc.gov/Cancer/USCS/DataViz.htmliii CDC.
https://www.cdc.gov/hepatitis/abc/index.htmiv CDC.
https://www.cdc.gov/diabetes/pubs/pdf/hepb_vaccination.pdfv CDC.
https://www.cdc.gov/hepatitis/populations/diabetes.htmvi
CDC. https://www.cdc.gov/hepatitis/hbv/bfaq.htmvii
CDC. https://www.cdc.gov/hepatitis/hbv/hbvfaq.htmviii
CDC. https://www.cdc.gov/diabetes/pubs/pdf/hepb_vaccination.pdfix
CDC. https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Apr 2024 to May 2024
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From May 2023 to May 2024